Pediatric Brain Tumor Clinical Trials
Questions about patients' participation in the following clinical trials can be directed to the study coordinator at (415) 353-9387 or a nurse practitioner at (415) 514-0238.
Newly Diagnosed Tumor
A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma ( Children’s Oncology Group Study ACNS0822). Study Details — TEMPORARILY CLOSED FOR PROTOCOL AMMENDMENT
Diffuse Intrinsic Brainstem Glioma (DIPG)
A Phase 1 Study of MK-1775 (IND#116459) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas (Children’s Oncology Group Study ADVL1217). Study Details
Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (Dana Farber Cancer Institute Study DFCI-DIPG). Study Details
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years (Childrens Oncology Group Study ACNS0831). Study Details
Medulloblastoma and Primitive Neural Ectodermal Tumor (PNET)
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial (Children's Oncology Group Study ACNS0331). Study Details.
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate (Children's Oncology Group Study ACNS0334). Study Details.
CNS Germ Cell Tumors
Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) (Children’s Oncology Group Study ACNS1123)
Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children (Pacific Pediatric Neuro-Oncology Consortium Study PNOC 001). Study Details
Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children with Recurrent/Refractory BRAFV600E-mutant gliomas (Pacific Pediatric Neuro-Oncology Consortium Study PNOC 002). Study Details
A Phase II and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma (PBTC 029). Study Details
A Phase I Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors (Amgen Study 20050252). Study Details.
Temozolomide with Irinotecan Versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial (Children’s Oncology Group Trial ACNS0821). Study Details
A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas (Children’s Oncology Group Trial ACNS1022). Study Details
A Phase 1 study of XL184 (cabozantinib) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors (Children’s Oncology Group Trial ADVL1211). Study Details
A Phase I Study of Sirolimus in Combination with Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults with Relapsed and REfractory Solid Tumors. Study Details
A Phase 1 study of AMG 386 (IND#114215), an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, including CNS Tumors (Children’s Oncology Group Trial ADVL1115). Study Details
Trials Studying Late Effects of Treatment
Neurocognitive Brain Tumor Study. This is a prospective study to test the feasibility of a computerized neurocognitive training program in children with brain tumors. (This is a UCSF study).
Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer (Children's Oncology Group Trial ALTE07C1). Study Details